Sparks Valuation Pharmaust, page-62

PAA's Upcoming and Exciting Newsflow:

1. MND: Commencement of OLE (Jan2024)
2. Canine: The canine market research report (Jan2024)
3. Corporate: Quarterly (Jan2024)
4. MND: FDA feedback (by 13 Feb 2024)
5. MND: Pre-Investigational New Drug (Pre-IND) meeting
6. Canine: MAST top line research results (1Q2024)
7. MND: FDA ODD decision (1Q2024)
8. MND: FightMND notification of successful grant application (July2024)
9. MND: Opening an IND application
10. MND: Initiating the Phase 2/3 clinical study, (2Q2024)
11. MND: Acceptance into Healey ALS platform
12. Canine: FDA approval of PAA’s Investigational New Animal Drug (INAD) application (3-4 months)
13. Canine: Commencement of field study (2024—25) > commercialization (2026)
14. Corporate: Creation of Scientific Advisory Board
15. MND: Liquid formulation combined with novel packaging

Patient survival time since diagnosed

	19 Jan 2024 (days)*	Additional days	31 Jan 2024 (days)
1	A - 782	12	794
2	B. - 738	12	750
3	C. - 855	12	867
4	D. - 1083	12	1095
5	E. - 841	12	853
6	* From Bucky’s post

SPARK MPL Valuation (MND and Canine cancer ONLY) - approx $1.00 per share

Now that gets the juices following